You Don’t Have to Take On
An Exceptional Opportunity: The Symmetry Study
NASH is a common form of liver disease caused by fat cells stored in the liver, and accompanied by inflammation and liver cell damage. Over time, NASH can cause liver fibrosis (scarring) and may lead to cirrhosis or liver cancer. The Symmetry study (AK-US-001-0103) is researching an investigational drug called efruxifermin (EFX) to determine if it can reverse liver damage in people with compensated cirrhosis due to NASH. And if you are 18 to 75 years of age and have been diagnosed with NASH, you may qualify to participate.
EFX is designed to target compensated cirrhosis due to NASH by reducing liver fat, inflammation, and scarring. The purpose of the Symmetry study is to evaluate the safety and effectiveness of this investigational drug versus placebo in patients with NASH. “Investigational” means that this drug has not yet been FDA approved and its use is being allowed for research purposes only.
If you qualify for the Symmetry study and choose to participate, you will be enrolled for approximately 24 months, during which you’ll be randomly assigned to receive either EFX or placebo. A placebo looks just like the investigational drug but contains no active medication. Neither you nor the study doctor will know which you are receiving until the end of the study, but in the case of an emergency, the study doctor can quickly find out.
All study-related office visits, medical procedures, laboratory tests, and EFX or placebo will be provided at no cost. Reimbursement for time and travel may also be available.
About Clinical Research
Every day, clinical research uncovers new information about medical conditions and their treatment.
If you have any questions, don’t hesitate to contact us.